Acetylation within the globular core domain of histone H3 on lysine 56 (H3K56) has recently been shown to have a critical role in packaging DNA into chromatin following DNA replication and repair in budding yeast 1, 2 . However, the function or occurrence of this specific histone mark has not been studied in multicellular eukaryotes, mainly because the Rtt109 enzyme that is known to mediate acetylation of H3K56 (H3K56ac) is fungal-specific 3,4 . Here we demonstrate that the histone acetyl transferase CBP (also known as Nejire) in flies and CBP and p300 (Ep300) in humans acetylate H3K56, whereas Drosophila Sir2 and human SIRT1 and SIRT2 deacetylate H3K56ac. The histone chaperones ASF1A in humans and Asf1 in Drosophila are required for acetylation of H3K56 in vivo, whereas the histone chaperone CAF-1 (chromatin assembly factor 1) in humans and Caf1 in Drosophila are required for the incorporation of histones bearing this mark into chromatin. We show that, in response to DNA damage, histones bearing acetylated K56 are assembled into chromatin in Drosophila and human cells, forming foci that colocalize with sites of DNA repair. Furthermore, acetylation of H3K56 is increased in multiple types of cancer, correlating with increased levels of ASF1A in these tumours. Our identification of multiple proteins regulating the levels of H3K56 acetylation in metazoans will allow future studies of this critical and unique histone modification that couples chromatin assembly to DNA synthesis, cell proliferation and cancer.
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H3K56 acetylation has a critical role in regulating chromatin assembly following DNA synthesis 1,2 , chromatin disassembly during transcriptional activation 5 and cell survival 1 in yeast. Although H3K56ac clearly exists in Drosophila 6, 7 , it is not known whether these functions of H3K56ac extend to multicellular eukaryotes. To investigate the function of H3K56ac in higher eukaryotes ( Supplementary  Fig. 1 ), we asked whether histones carrying K56ac are incorporated into chromatin following DNA repair in Drosophila S2 cells using antibodies specific to H3K56ac (Supplementary Fig. 2 ). Exposure to hydroxyurea, methyl methane sulphonate (MMS) or ultraviolet irradiation increased the level of H3K56ac on chromatin in a dosedependent manner, as determined by western blotting (Fig. 1a and Supplementary Fig. 3 ) and immunofluorescence analyses ( Fig. 1b and Supplementary Fig. 4 ). Notably, these agents did not result in an accumulation of cells in S phase ( Supplementary Fig. 5 ). Consistent with the requirement for the histone chaperone antisilencing function 1 (Asf1) for H3K56 acetylation in yeast 8 , we found that Drosophila Asf1 is required for both the endogenous level ( Fig. 1c and Supplementary Fig. 6 ) and the DNA-damage-induced increase in the level (Fig. 1d) of H3K56ac in vivo. Notably, knockdown of another histone chaperone, chromatin assembly factor 1 (Caf1), also markedly decreased the levels of H3K56ac on chromatin (Fig. 1e) . However, knockdown of Caf1, but not Asf1, resulted in accumulation of H3K56ac in the soluble protein fraction (Fig. 1f) . As such, these results demonstrate that Drosophila Caf1 is required for the assembly of histones carrying the K56ac mark into chromatin, whereas Asf1 is required for H3K56 acetylation per se. Using Drosophila embryos cycling synchronously between S and M phases, we detected no apparent difference in the amount of H3K56ac present in S-or M-phase nuclei (Fig. 1g) . During mitosis, the staining of H3K56ac closely followed that of the condensed mitotic chromosomes, indicating that the H3K56ac mark is indeed on the chromatin rather than free in the nucleus. This is in contrast to the situation in yeast, where high levels of H3K56ac are only detectable in S phase 9 . The enzymes that acetylate and deacetylate H3K56 are unknown in multicellular organisms. Given the structural similarity between the yeast H3K56 histone acetyl transferase (HAT) Rtt109 (ref. 10 ) and p300/CBP 11 , we investigated the potential role of Drosophila CBP 12 in acetylating H3K56. Treatment of S2 cells with curcumin-an inhibitor of the CBP/p300 family of HAT proteins 13 -markedly decreased H3K56ac levels (Fig. 2a) . Furthermore, knockdown of CBP ( Fig. 2b and Supplementary Fig. 6 ), but not knockdown of another H3-specific HAT, Gcn5 (also known as Pcaf; ref. 14; Supplementary  Fig. 6 ), blocked acetylation of H3K56 in both the absence and the presence of DNA damage (Fig. 2b, c) , indicating that CBP is the major H3K56 acetylase in Drosophila. Consistent with the idea that Asf1 and CBP function together to acetylate H3K56 in flies, CBP coimmunoprecipitates with Asf1 ( Supplementary Fig. 7 ). The NAD-dependent histone deacetylases (HDACs) Hst3 and Hst4 are the major H3K56ac HDACs in yeast 15, 16 . To investigate whether an NAD-dependent HDAC mediates H3K56 deacetylation in Drosophila, we treated S2 cells with the NAD-dependent HDAC inhibitor nicotinamide 17 . Treatment with nicotinamide, but not with the related molecule nicotinic acid, resulted in increased H3K56ac levels ( Fig. 2d and Supplementary Fig. 8 ). Of the six Drosophila NAD-dependent HDACs, Sir2 is the closest counterpart of yeast Hst3 and Hst4. Indeed, knockdown of Drosophila Sir2 greatly increased the level of H3K56ac (Fig. 2e and Supplementary Fig. 6 ), indicating that Sir2 deacetylates H3K56ac in Drosophila.
Besides one global mass spectrometry study of histone modifications 18 , H3K56ac has not previously been reported in human cells. By western blot analysis of chromatinized histones from HeLa cells, we clearly detected H3K56ac in humans (Fig. 3a) . The amount of H3K56ac in HeLa and S2 cells was similar ( Supplementary Fig. 9 ), and mass spectrometry analysis confirmed the existence of H3K56 acetylation in HeLa cells (Supplementary Fig. 10 ). Furthermore, the amount of H3K56ac on chromatin increased in response to gammairradiation in a dose-dependent manner (Fig. 3a) . The clear colocalization of H3K56ac and the phosphorylated histone variant H2AX (H2AXp) following DNA damage indicated that the assembly of histones carrying H3K56ac is enriched at sites of DNA repair (Fig. 3b) . The levels of H3K56ac on human chromatin were also increased following ultraviolet, MMS and hydroxyurea treatment (Fig. 3c) . By flow cytometry analysis, we found that, even in the absence of DNA damage, human cells in all stages of the cell cycle have abundant H3K56ac staining ( Supplementary Fig. 11 ).
Consistent with the reduced level of acetylation of H3K56 in human cells on curcumin treatment ( Supplementary Fig. 12 ), we found that both CBP and p300 contribute to acetylation of H3K56 in human cells (Fig. 3d , e and Supplementary Fig. 13 ). Furthermore, CBP and p300 directly acetylate histone H3 on lysine 56 in vitro (Fig. 3f, g ), with high efficiency as determined by mass spectrometry analysis ( Supplementary Fig. 13 ). Acetylation of H3K56ac by the yeast HAT Rtt109 requires that histones H3-H4 be pre-bound to the histone chaperone Asf1 (ref. 19) . However, this is not the case with CBP in vitro, because it efficiently acetylated H3K56 irrespective of whether the histones were bound to Asf1 (Fig. 3f) . Towards identifying the human HDAC for H3K56, we found that treatment of human cells with nicotinamide greatly increased the level of H3K56ac (Fig. 3h) , implicating an NAD-dependent HDAC. Small interfering RNA (siRNA) knockdown analyses of human SIRT1 and SIRT2 indicated that both enzymes contribute to deacetylation of H3K56 in human cells (Fig. 3i) . Indeed, both recombinant human SIRT2 and SIRT1 deacetylated H3K56 in vitro, with SIRT2 being the more active enzyme ( Fig. 3j and Supplementary Fig. 14) . Treatment of human cells with sodium butyrate notably increased H3K56ac levels ( Supplementary Fig. 12 ), additionally implicating a class I or class II HDAC in H3K56 deacetylation. Taken together, these data reveal that human CBP and p300 are the H3K56 acetylases whereas SIRT2 and SIRT1 are H3K56ac deacetylases.
Next, we investigated whether either of the two forms of the human ASF1 histone chaperone, ASF1A and ASF1B, is involved in H3K56 acetylation. Using yeast strains that express equivalent levels of human ASF1A, human ASF1B or Drosophila Asf1 in the place of the yeast Asf1 protein 20 , it was apparent that human ASF1A and Drosophila Asf1, but not human ASF1B, can assist yeast Rtt109 in the acetylation of H3K56 (Fig. 4a) . In agreement, knockdown of ASF1A decreased the amount of H3K56ac in human cells more than knockdown of ASF1B whereas the combined knockdown of both ASF1A and ASF1B resulted in no detectable H3K56ac (Fig. 4b) . The requirement for ASF1 for H3K56 acetylation in vivo, but not in vitro, indicates that additional constraints exist in vivo. We also found that human ASF1 is required for the increase in levels of H3K56ac on chromatin following DNA damage, whereas human CAF-1 is required for the assembly of the H3K56 acetylated histones onto DNA (Fig. 4c, d ). Further supporting the role of ASF1A versus ASF1B in H3K56 acetylation, there is a notable correlation between levels of H3K56 acetylation and ASF1A but not ASF1B in a wide variety of normal and cancerous human tissues (Fig. 4e) (Fig. 4f) . Furthermore, H3K56ac staining also occurred in cancer Fig. 4g ). These data indicate that H3K56ac levels correlate with tumorigenicity rather than proliferation. Consistent with the increased level of H3K56ac in dedifferentiated cancer cells, we also find that H3K56ac levels positively correlate with the undifferentiated nature of cells. For example, H3K56ac levels are higher in embryos than in cell lines (Fig. 4h ) and the level of H3K56ac rapidly drops on in vitro differentiation of cell lines ( Fig. 4i and Supplementary Fig. 18 ). Recent yeast studies indicate that H3K56ac increases the ability of histones to bind to CAF-1, which subsequently deposits the histones onto newly synthesized DNA 1, 2 . This is also likely to be the case in humans, given that knockdown of CAF-1 blocks incorporation of H3K56ac into chromatin (Figs 1f and 4d ) and that inhibition of ASF1 blocks DNA replication and chromatin assembly of newly synthesized DNA [22] [23] [24] . In agreement, CBP/p300 promote DNA replication and cell proliferation 25, 26 . Furthermore, p300 is recruited to sites of DNA synthesis via its interaction with PCNA 27 , consistent with a direct role for CBP/p300 in promoting chromatin assembly via K56 acetylation after DNA synthesis. It is also intriguing that the HAT activity of human CBP is highest at the G1/S boundary-the time at which massive amounts of newly synthesized H3 is produced to assemble the newly replicated genomes into chromatin 28 . We propose that the CBP/p300-mediated acetylation of H3K56 promotes the subsequent assembly of newly synthesized DNA into chromatin in metazoans ( Supplementary Fig. 1) , the inhibition of which negatively feeds back to block DNA replication and cell proliferation. Given that the H3K56ac mark is rapidly removed by histone deacetylases after histone incorporation onto newly replicated DNA in yeast 15, 16 , it will be interesting to determine whether the H3K56ac deacetylation process is defective in undifferentiated and dedifferentiated cancer cells. Alternatively, the increased levels of H3K56ac in cancer cells and undifferentiated cells may reflect hyperdynamic exchange of histones 29 in undifferentiated cells that is lost on differentiation. 
METHODS SUMMARY
Yeast strains and tissue culture. Genotypes of strains and tissue culture details are described in the Methods. Histone isolation and western blotting. Histone extraction was performed as described previously 30 . In brief, following nuclear pellet isolation, soluble chromatinized histones were extracted with 0.4 M and 0.25 M HCl for S2 cells and HeLa cells, respectively, followed by TCA precipitation. NP40-induced extraction of detergent-soluble proteins is detailed in the Methods. In brief, following treatment with 0.1% NP40 for 10 min, centrifugation at 1,800g. for 10 min led to the separation of supernatant and pellet fractions. Antibody details are provided in the Methods. Immunofluorescence. Immunofluorescence following 0.5% Triton X-100 extraction was performed as described previously 23 . RNA interference. Knockdowns were performed in S2 cells as described previously 23 .
In brief, double-stranded RNA was generated by in vitro transcription using the Megascript kit from Ambion. After testing the quality of each double-stranded RNA, it was transfected into S2 cells for different lengths of time to ensure complete silencing of the gene of interest, as determined by western blotting. Primer sequences are availableonrequest.siRNAsforsilencinginHeLacellswereobtainedfromDharmacon. HAT and HDAC assays. Recombinant human CBP, p300, SIRT1 and SIRT2 were obtained from Biomol. Following a 10 min preincubation of HAT with purified recombinant Asf1-H3H4 complexes, purified Drosophila core histones or H3-H4 tetramers at 30 uC, acetyl-CoA was added and incubated at 30 uC for 10 min, followed by TCA precipitation. For HDAC assays, following acetylation of H3K56 by CBP/p300, curcumin was added to inhibit CBP/p300 and the histones carrying H3K56ac were incubated with SIRT1 or SIRT2 in the presence of NAD at 30 uC for the indicated length of time. 20 The 'hASF1A' strain is BAT016; MATa ade2-1 leu2-3,112 his3-11 trp1-1 ura3-1 TEVIIL::URA HMRa::ADE2 asf1::hAsf1a-13myc KAN 20 . The 'hASF1B' strain is KDY006; MATa ade2-1 leu2-3,112 his3-11 trp1-1 ura3-1 TEVIIL::URA HMRa::ADE2 asf1::hAsf1b-13myc KAN 20 . Tissue culture media. Drosophila S2 cells were maintained in Schneider's media supplemented with 10% FBS at 30 uC. HeLa cells were grown in DMEM media supplemented with 10% FBS at 37 uC in 5% CO 2 supply. Unless otherwise stated, curcumin was used at 100 mM for 24 h, nicotinamide, nicotinic acid or sodium butyrate were used at 25 mM for 12 h. SHSY-5Y cells were grown in media composed of 50% Ham's F12 and 50% MEM, supplemented with 10% FBS at 37 uC in 5% CO 2 supply. SHSY-5Y cells were treated with 0.02 mM retinoic acid for 3 to 6 days to induce differentiation. MCF7 cells were grown in DMEM supplemented with 10% FBS at 37 uC in 5% CO 2 supply. MCF10A cells were grown in DMEM supplemented with 10% FBS, 0.01 mg ml 21 insulin, 0.5 mg ml 21 hydrocortisone, 0.02 mg ml 21 EGF and 0.1 mg ml 21 cholera toxin. For trypsinization, 0.05% trypsin-EDTA was used for MCF10A/12A, and 0.25% trypsin-EDTA was used for the rest of the cell lines. Antibodies and commercial blots. Drosophila H3K56ac was detected using an H3K56ac-specific antibody from Upstate (catalogue number 07-677) whereas human H3K56ac was detected using a rabbit monoclonal H3K56ac specific antisera from Epitomics (2134-1). Gcn5 was detected with an antibody from Abcam (ab52787), total H3 was detected with an antibody from Abcam (ab1791), H3K9ac was detected with an antibody from Upstate (07-352), human CBP was detected with an antibody from Abcam (ab2832) and human p300 was detected with an antibody from Abcam (ab61217). Asf1 was detected with a previously described antibody 32 . The anti-phospho H2AX antibody was from Upstate (07-164). Commercial tissue blots, having normal and cancerous samples, were procured from G Biosciences (TB56 Set I, II). These blots contain lysates (in a denaturing buffer supplemented with a cocktail of protease inhibitors to minimize proteolytic degradation) extracted from human normal and tumour tissues. Equal amounts of proteins were loaded on a 4-20% gradient denaturing PAGE, followed by transfer in a PVDF membrane. Isolation of pellet and supernatant fractions. NP40-induced extraction of detergent-soluble proteins was performed as described elsewhere 33 . In brief, following treatment with 0.1% or 0.5% NP40 for 10 min, centrifugation at 1,800g. for 10 min led to the separation of non-chromatin supernatant and chromatin pellet fractions. The pellet fractions were subsequently purified and analysed by western blotting for the presence of H3K56Ac. Supernatant (nonchromatin) and pellet (chromatin) fractions were resolved following 0.1% NP40 treatment as mentioned elsewhere 34 . Isolation of histones from Drosophila embryos. The histone extraction from stage 9-13 Drosophila embryos was performed according to standard protocol 35 . In brief, the embryos were homogenized in lysis buffer (15 mM Tris, pH 7.5, 60 mM KCl, 15 mM NaCl, 3 mM EDTA, 0.1 mM EGTA, 0.15 mM spermine, 0.5 mM spermidine, 0.2% NP40, 10 mM NaF and protease inhibitors) supplemented with a cocktail of HDAC inhibitors. The nuclear pellet was subsequently treated with 0.4 M HCl for 1 h for histone extraction. The extracted histones were subsequently TCA precipitated and analysed for the H3K56 acetylation levels. Immunoprecipitation. S2 whole-cell extracts were prepared using RIPA buffer (150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8, 10 mM NaF, 0.4 mM EDTA, 10% glycerol and protease inhibitors) supplemented with protease inhibitors. The pre-blocked protein-G-Sepharose-bound fly Asf1 antibody was then incubated with whole-cell extracts. Following extensive washes, the bead-bound protein complexes were analysed by western blotting using fly CBP or H3 antibodies. For CAF-1 and ASF1A/B, the siRNA transfection time was for 48 h. For CBP, p300, SIRT1 and SIRT2, the transfection time was 72 h. Flow cytometry. After the different treatments, the cells were washed with PBS and subject to ethanol fixation for at least 1 h. The cells were then Tritonextracted (0.05%), blocked in 1% BSA, and stained with H3K56ac antibody (Epitomics) at 1:250 dilution for 1 h. After extensive washing in PBST, the cells were put in Alexa-568-conjugated secondary antibody for 1 h at 1:1,000 dilution. The cells were extensively washed, 0.5 mg ml 21 RNase treated and finally stained with propidium iodide at 10 mg ml 21 final concentration for 1 h in the dark. The cell cycle stages and K56ac staining intensities were then measured by flow cytometry. Immunohistochemistry. After deparafinizing, slides were rinsed in ethanol. Antigen retrieval was performed with 10 mM sodium citrate for 5 min at 22 psi. The staining was performed with the I-VIEW enhanced DAB kit. Counterstaining was performed with Mayer's haematoxylin, and the mounting media used was Cytoseal 60. IMH-346 and IMT-01233 tissue array slides were procured from Imgenex. Additional slides for normal and tumour skin, thyroid, cerebellum, colon, larynx and ovary tissues were analysed from the UCCC Pathology core. Each of the sample specimens was pathologically confirmed before carrying out the immunohistochemistry. DNA-damaging treatments. Unless otherwise indicated, 0.05% MMS and 150 mM hydroxyurea treatment was performed for 12 h. 49,995 J m 22 of ultraviolet or 1, 1.25 and 1.5 Gy gamma irradiation were given to visualize the damage foci.
Immunofluorescence. In brief, following 4% formaldehyde fixation, cells were permeabilized by 0.5% Triton X-100, blocked in 1% BSA, and treated with primary antibody followed by Alexa-488-conjugated secondary antibody. Vectashield mounting medium containing DAPI was used for DNA staining. H3K56ac and H2AXp antibodies were detected using Alexa-488-or Alexa-568-conjugated secondary antibody, respectively, following previously described methods 32 . Mass spectrometry analysis. The histone K56 acetylation analysis by mass spectrometry sample digestion A standard in-gel digestion protocol was used based on previously used methods 40, 41 . Iodoacteamide (IAM) was used for Cys alkylation. Liquid chromatography-tandem mass spectrometry data acquisition digests were analysed on a LTQ-ICR hybrid mass spectrometer (LTQ-FT Ultra, Thermo Fisher). Peptide desalting and separation was achieved using a dual capillary/nano pump HPLC system (Agilent 1200). On this system 8 ml of sample was loaded onto a trapping column (ZORBAX 300SB-C18, dimensions 5 3 0.3 mm (5 mm); Agilent Technologies) and washed with 5% acetonitrile, 0.1% formic acid at a flow rate of 15 ml min 21 for 5 min. At this time the trapping column was put online with the nano-pump at a flow rate of 350 nl min 21 . An 80 min gradient from 8% ACN to 32% ACN was used to separate the peptides. The column was made from an in-house pulled 360/100 nm (outer/inner diameter) fused silica capillary using a model P-2000 laser puller (Sutter Instrument Co.). The column was packed 15 cm in length with Jupiter C18 resin (Penomenex). The column was kept at a constant 40 uC using an in-house built column heater. The column effluent was coupled directly to the mass spectrometer with an in-house built nanospray ion source. Data acquisition was performed using the instrument supplied Xcalibur (version 2.0.7) software. The 90-min liquid chromatography runs were monitored by sequentially recording the precursor scan (MS) followed by three collision-induced dissociation (CID) acquisitions (MS/MS). Normalized collision energies were employed using helium as the collision gas. MS survey scans were acquired in the ICR cell at a resolution of 25,000 at 400 m/z. After two acquisitions of a given ion within 45 s, the ion was excluded for 150 s. Data analysis. The manufacturer-supplied extract_msn script was used to create de-isotoped, centroided peak lists from the raw spectra (.mgf format). These peak lists were searched against the SwissProt database (v54.8) using Mascot server (Version 2.2, Matrix Science). For searches, mass tolerances were 610 parts per million (p.p.m.) for MS peaks, and 60.6 Da for MS/MS fragment ions. Trypsin specificity was used allowing for one missed cleavage. The modifications of Met oxidation, protein N-terminal acetylation, peptide N-terminal pyroglutamic acid formation (Q), lysine acetylation and lysine mono-, di-and tri-methylation were allowed for. Peptides were required to reach a score of 6 and proteins were filtered at a significance of P , 0.005 and required bold red hits (top match for a given spectrum). Semiquantification of K56 acetylation. The tryptic peptide resulting from the unacetylated K56 form of H3 was 'K.STELLIR.K'. This peptide was compared to the tryptic peptide resulting from the K56 acetylated form of H3 'R.YQ-AcK-STELLIR.K'. Trypsin cleavage does not occur on the C-terminal side of acetylated K56 due to the loss of the positive charge. Extracted ion chromatograms were calculated for the range m/z 416.23-416.27 for the 'STELLIR' peptide. It was confirmed that the peak from ,27 to 30 min corresponded to the 'STELLIR' peptide, based on assignment of several CID spectra. Likewise the extracted ion chromatogram from 646.81 to 646.91 was used to calculate the acetylated form In Fig. 4e of this Letter, one band was incorrectly labelled. We thank B. Lüscher for drawing this to our attention. The correctly labelled version of the figure is provided below. As such, the statement that there is ''a notable correlation between levels of H3K56 acetylation and ASF1A but not ASF1B in a wide variety of normal and cancerous human tissues'' is no longer accurate. However, the main purpose of Fig. 4e is still valid, which was to show by western blotting analysis that the level of H3K56ac is much higher in some tumours as compared to the matching normal tissue.
We also note that although the fractionation of the total stained proteins in Figs 1f and 4d did not show obvious differences, the fractionation of histones and tubulin was effective between the supernatant and pellet fractions (see Supplementary Figure) .
We also omitted to state that the ultraviolet light used in our analysis was 312 nm UVB, which causes 1% of the amount of DNA damage as 254 nm UVC.
Supplementary Information is linked to the online version of the paper at www.nature.com/nature. 
